In (1), the authors wish to correct Table 2 that was published on page 561. In the table, the numbers in parentheses have been added next to the study and some of the percentages have been amended. The corrected table is published below:

Table 2.   Major allergen content and efficacy for different grass pollen SLIT preparations (Reductions were calculated by ([Active – Placebo]/Placebo)x100)
StudyPatients groupMajor allergen content in the peak dose acc. to the cited publicationsDuration of SLIT [months]Efficacy active vs. placebo (mean reduction) on
Combined SMS scoreSymptom scoreMedication
  1. *On peak grass pollen season

Moreno-Ancillo et al. 2007 (SLIT one®) (44)Adults2 μg Phl p 510No differencesNo differencesNo differences
Bufe et al. 2001 (Sublivac®) (45)Children9.1 μg Phl p 536No differencesNo differencesNo differences
Emminger et al. 2008 (Grazax®) (46)Adults15 μg Phl p 534 (3 years)Not available−29%−40%
Didier et al. 2009 (300IR) (Oralair®) (38)Adults20 μg grasses group 5 allergen4–5−30%−27%−35%
Pfaar, Klimek 2008 (AllerSlit® forte) (19) and Worm 2008 (18)Adults40 μg grasses group 5 allergen18−46%Not availableNot available
Wahn et al. 2009 (Oralair®) (31)Children20 μg grasses group 5 allergen 5−27%−28%−24%
Bufe et al. 2009 (Grazax®) (30)Children15 μg Phl p 56–7−23%*−20%*−27%*


  1. Top of page
  2. Reference
  • 1
    Wahn U., Malling H.-J. and Kleine-Tebbe J. Sublingual immunotherapy in children - ready for prime time? PAI 2010: 21: 55963.